Navigation Links
Emmaus Life Sciences Announces Closing Of $7.5 Million Private Placement
Date:9/16/2013

TORRANCE, Calif., Sept. 16, 2013 /PRNewswire/ -- Emmaus Life Sciences, Inc. (the "Company," or "Emmaus"), a biotherapeutics company dedicated primarily to the discovery, development and commercialization of innovative and cost effective treatments and therapies for debilitating rare diseases, today announced it has raised approximately $7.5 million in gross proceeds from a private placement to accredited investors, including two institutional investors.

In connection with the financing, Emmaus has agreed to expand its board of directors to eight members, with three newly-created directorships to be filled by qualified representatives of certain participants in the financing.

The net proceeds from the private placement will be used primarily for research and development, including the completion of the company's Phase 3 clinical trial for the treatment of sickle cell disease, commercialization costs, and for working capital and general corporate purposes.

T.R. Winston & Company served as placement agent to Emmaus.

The shares of common stock and warrants described above were offered and sold to a limited number of institutional and accredited investors. The shares of common stock and warrants, and the shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.

This press release is issued pursuant to Rule 135(c) under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of the securities in any state or jurisdiction in which such offer, sol
'/>"/>

SOURCE Emmaus Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Garage Start-ups Now Possible in Life Sciences Industry
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. DiaTech Life Sciences Announces Medical Advisory Board
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The global market for molecular diagnostics is ... to a new study by Grand View Research, Inc. ... subsequent introduction of advanced cancer diagnostic technologies are expected ... next six years. Moreover, the growing global base of ... with disease triggering lifestyle habits such as smoking and ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2014 on Wednesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2014 ...
(Date:7/30/2014)... FRANCISCO , July 30, 2014 ... Congress evaluated the safety and efficacy of CSL ... rejection following kidney transplants in highly sensitized patients. ... inhibitor of the complement system. The ... in significant increases in the levels of complement ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 2009 Senomyx, Inc. (Nasdaq: SNMX ) will ... 7, 2009 before the opening of the U.S. financial markets. ... a live Internet broadcast that will provide a corporate update ... same day at 11:00 a.m. Eastern Time (8:00 a.m. Pacific ...
... Fla., April 22 OmniComm Systems, Inc. (OTC Bulletin ... the clinical trials market today announced its results of ... the first quarter of 2009 increased approximately 139% to ... 2008. Gross profit margin improved to 79.5% for the ...
... (Nasdaq CM: INSM ), a biopharmaceutical ... call on Wednesday, May 13th at 8:30 AM ET, ... 2009. Insmed intends to issue its quarterly financial ... 13th.To participate in the live conference call, please dial ...
Cached Biology Technology:SENOMYX, INC. FIRST QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR MAY 7, 2009 2OmniComm Systems Announces 1st Quarter Results of Operations 2OmniComm Systems Announces 1st Quarter Results of Operations 3Insmed to Host First Quarter 2009 Conference Call 2
(Date:7/31/2014)... of animal models against the highly infectious and virulent ... disease that kills approximately 30,000 Americans annually. The research ... Immunity . , In the study, the vaccine ... toxins produced by C. difficile , as well ... that mimics the human disease, after only two immunizations. ...
(Date:7/31/2014)... exposure to loud noise alters how the brain ... speech sounds, according to neuroscientists at The University ... published this week in Ear and Hearing ... noise-induced hearing loss affects the brain,s recognition of ... all corners of the population, affecting an estimated ...
(Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... (CHICAGO - Sept. 30, 2009) U.S. Environmental Protection Agency,s ... of a dioxin exposure study conducted by the University ... the study was conducted well and provided useful, scientifically ... to help EPA fully evaluate human exposure to levels ...
... KINSTON, N.C., Oct. 1 Spatial Integrated Systems, ... integration of solutions incorporating next-generation digital 3D data ... United States patent application has been published for ... 3-dimensional image rendering" under Publication No. US2009/0169095A1. , ...
... University of Warwick and Rothamsted Research have been awarded ... (BBSRC) in partnership with Syngenta, to research the decline ... have fallen by 10-15% over the last 2 years; ... 30% for 2008. Since the declines were first reported ...
Cached Biology News:EPA reviews Univ. of Michigan dioxin study 2Spatial Integrated Systems, Inc. Files Patent Application 2£1 million award to address honeybee decline 2£1 million award to address honeybee decline 3
... Osmometer for both 0.2 and 2.0 mL samples for freezing point determinations. ... Bar code reading capability with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: